The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel. We studied 93 Caucasian women with ovarian cancer treated with paclitaxel and carboplatin. Using sparse sampling and nonlinear mixed effects modeling, the individual clearance of unbound paclitaxel was estimated from total plasma paclitaxel and Cremophor EL. The geometric mean of clearance was 385 l h -1 (range 176-726 l h -1 ). Carriers of CYP2C8*3 had 11% lower clearance than non-carriers, P ¼ 0.03. This has not been shown before in similar studies; the explanation is probably the advantage of using both unbound paclitaxel clearance and a population of patients of same gender. No significant association was found for the ABCB1 variants C1236T, G2677T/A and C3435T. Secondarily, other candidate single-nucleotide polymorphisms were explored with possible associations found for CYP2C8*4 (P ¼ 0.04) and ABCC1 g.7356253C4G (P ¼ 0.04).
Introduction
Paclitaxel is used to treat cancer of the breast, lung, ovary and other neoplasms. In ovarian cancer, the standard of care in most clinics is post-surgery combination chemotherapy with carboplatin and paclitaxel. Although the initial response rate is as high as 70-85%, 1 most patients with advanced stages eventually relapse and die of the disease. Paclitaxel is dosed normalized to body surface area (BSA) and in most regimes infused over 1, 3 or 24 h. The doselimiting toxicities are neutropenia and neuropathy. There is a large interindividual variability in toxicity and therapeutic effect of paclitaxel in ovarian cancer treatment, which remains a clinically relevant problem with implications on survival and quality of life of the patients and practical with regard to the handling of dose delay, dose reduction or cessation of the treatment. 2 Several possible causes of this variability have been suggested; especially the notion that single-nucleotide polymorphisms (SNPs) in certain genes could cause significant changes in the affinity and/or expression of key transporters or metabolizing enzymes. Paclitaxel is metabolized to inactive compounds by CYP2C8 and CYP3A4 in the liver, [3] [4] [5] and is also a substrate for the adenosine triphosphate-driven efflux pump P-glycoprotein encoded by the ABCB1 gene. 6 A host of other candidate genes linked to paclitaxel were picked for exploratory analysis: they include CYP3A5, ABCC1, ABCC2, ABCG2, ABCC10, CYP1B1 and SLCO1B3. [7] [8] [9] [10] [11] [12] [13] These are all drug transporters except CYP3A5 that has a substrate range similar to CYP3A4, and CYP1B1 that has been implied to have a role in taxane metabolism and therapeutic effects. 7 Transporters can facilitate elimination by actively transporting the drug into a metabolizing cell or by actively exporting drug to the bile.
Total plasma paclitaxel elimination has previously been shown to be nonlinear. 14 This has been attributed to saturable transport 15 and saturable binding 16 but also to paclitaxel being trapped in micelles formed by adjuvant Cremophor EL (CrEL). [17] [18] [19] Considering the unbound clearance of paclitaxel instead of total plasma clearance can therefore be expected to give a clearer estimate of the effect of genetic variants on the elimination processes.
The aim of this study was to evaluate the elimination capacity of patients with the CYP2C8*3, ABCB1 C1236T, G2677T/A and C3435T variants in a confirmatory type analysis and other variants in CYP2C8 and ABCB1 as well as variants in CYP1B1, CYP3A4/5, SLCO1B3, ABCC1, ABCC2, ABCG2 and ABCC10 in an exploratory analysis. The study was initiated based on reports on CYP2C8*3 as having decreased paclitaxel metabolism 20, 21 and reports of a functional significance of ABCB1 SNPs with particular interest in C1236T, G2677T/A and C3435T; [22] [23] [24] the other candidate SNPs entered the study after it was initiated but the a priori distinction between confirmative and exploratory candidates was kept to meet the issue of multiple testing.
We present a prospective pharmacogenetic study on the population pharmacokinetics of paclitaxel in 93 Scandinavian Caucasian female patients with epithelial ovarian/ peritoneal cancer.
Patients and methods

Patients
Eligibility criteria included: candidates for paclitaxel/carboplatin chemotherapy, clinical or histopathological diagnosis of epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer, age X18 years, Caucasian, WHO/ECOG performance status p2, no concurrent malignant diseases and adequate contraception for women of child-bearing potential. All patients provided written and verbal consent before entering the study as per Helsinki declaration. All patients were scheduled for six to nine courses of paclitaxel (175 mg m -2 ), 3-h intravenous-infusion followed by carboplatin (Area Under the Curve 5-6 mg*min ml -1 ), every third week. Paclitaxel was administered in formulation with CrEL (polyoxyethyleneglycerol triricinoleate 35) at 5 ml per 30 mg paclitaxel. All patients were pretreated with steroid and histamine receptors H1 and H2 antagonists as recommended by national guidelines. Concurrently used drugs were recorded and compared with known inhibitors of CYP3A4/5 and CYP2C8. The study was approved by regional ethics committees of Southern Denmark and Lund, Sweden. Patients were recruited at oncology departments in Denmark and Sweden.
Blood sampling, paclitaxel and CrEL analysis Three consecutive samples were collected from one cycle from each patient. Plasma was sampled at noted time points; approximately at 3 h (just before end of infusion), at 5-8 h and at 18-24 h after start of paclitaxel infusion. Aliquots of whole blood for DNA extraction was kept at À20 1C or less. The total concentration of paclitaxel in plasma was estimated using a liquid-liquid extraction method and high-performance liquid chromatography with ultraviolet detection. Paclitaxel was purchased from Sigma, St Louis, MI, USA and docetaxel from Fluka, Buchs, CH. The extraction method was performed as described by Alexander et al. 25 The sample was transferred to a conical 300 ml polypropylene high-performance liquid chromatography micro vial. An aliquot of 40 ml was injected into a LaChrom high-performance liquid chromatography system (MerckHitachi, Darmstadt, Germany) and monitored at l ¼ 227 nm on the ultraviolet-detector. The separation was performed on a 50 Â 2.1 mm Gold C18 column (2.1 mm particle size) (Thermo, San Jose, CA, USA) at 30 1C using isocratic elution. The mobile phase consisted of acetonitrile: Milli-Q water: glacial acetic acid (35:65:0.1 v/v %). The flow rate was 0.2 ml min -1 . Calibration curves ranging up to 10 000 nmol l -1 was produced for each day of analysis and showed a good linearity (r ¼ 0.997). The intraday variability was o8.5% for paclitaxel. The interday variability (n ¼ 5 days) was analyzed for six concentration levels (75, 300, 750, 1500, 3500 and 8500 nmol l -1 ) and was o6% for paclitaxel. The accuracy for paclitaxel ranged from 89.2 to 101.8%. The lower limit of detection was 20 nmol l -1 and the lower limit of quantification was 25 nmol l -1 for paclitaxel. CrEL concentrations were determined by an earlier described method with minor changes. 26 The samples were analyzed in duplicate with a standard curve ranging from 0.1 to 1.0% and a spiked quality control sample. The sample concentration was interpolated from the nonlinear standard curve by second-order polynominal regression using GraphPad Prism version 5.0a (GraphPad software, La Jolla, CA, USA). The intra-and interday variation (CV) of the quality control sample was found to be 7.0 and 7.4%, respectively (n ¼ 10) and the intra-and interday accuracy (%-difference from the spiked 'true value') was þ 1 and À3%, respectively. The limits of quantification were set by the standard curve, which covered all plasma samples analyzed in the study.
Pharmakokinetic analysis
The clearance of unbound paclitaxel was estimated from total paclitaxel concentrations and CrEL concentrations in a nonlinear mixed effects analysis. This approach is described by Henningsson et al.; 27 in brief, we used a two compartment structure with total paclitaxel concentrations C p and Impact of CYP2C8*3 on paclitaxel clearance TK Bergmann et al unbound concentration C u described with the following equation: 27 The covariate model suggested by Henningsson et al. 27 with BSA explaining IIV (inter-individual variability) of clearance and volumes of distribution and bilirubin explaining IIV of unbound clearance was used without any changes as the basic model. In addition, age, performance status, smoking, alcohol, albumin, alkaline phosphatase and alanine aminotransferase were tested as covariates in a trial and error manner using likelihood ratio test in NONMEM. Age and performance status further explained IIV of clearance, lowering the objective function value 13.5 and 18.5 points respectively. Assuming that objective function value approximately is w 2 distributed, a true effect of the covariates seemed very likely (P-value o0.001) and both were added in the final model. No other covariates significantly contributed to IIV. Empirical Bayes estimates of unbound clearance of paclitaxel were obtained and are herein referred to as clearance. All analyses were performed with the firstorder conditional estimation method with interaction in NONMEM VI (Beal and Sheiner, University of California, San Francisco, CA, USA) and graphical diagnostics were obtained using the software Xpose 28 (Hooker, Karlsson and Jonsson, Uppsala University, Uppsala, Sweden) and PsN 29 ( Karlsson, Jonsson and Hooker, Uppsala University, Uppsala, Sweden).
Genotyping procedures
Genomic DNA was extracted from whole blood using standard methods. SNPs in CYP2C8, CYP3A4, SLCO1B3 (except G767C) and ABCB1(except A-1G) were determined using Pyrosequencing as previously described. [30] [31] [32] The variants in CYP1B1, CYP3A5, ABCC1, ABCC10 and G767C in SLCO1B3, A-1G in ABCB1 and rs2273697 in ABCC2 were genotyped using TaqMan pre-designed SNP genotyping assays by Applied Biosystems (Foster city, CA, USA). SNPs in ABCG2 and rs17222723 and rs8187710 in ABCC2 were genotyped using pairs of allele-specific primers (ASP) and a locus-specific primer (LSP) in SYBRgreen real-time PCR assays. The used primers were: rs8187710 (ABCC2) ASP:
0 . All real-time assays were performed using ABI PRISM 7700 or StepOnePlus from Applied Biosystems. Genotype calling using SYBRgreen was carried out by visual assessment by two persons separately.
ABCB1 haplotype inference
Haplotypes of the six ABCB1 SNPs were inferred using the software package PHASE (Stephens, University of Washington, Seattle, WA, USA), version 2.1 by Stephens et al. 33, 34 The program infers haplotype frequencies and the most likely individual haplotype using a Bayesian statistical method. We ran PHASE, with default settings 10 times. All runs returned 100% consistent calls. The inferred population frequencies agreed well with Kroetz et al. 35 who analyzed the haplotype structure of the ABCB1 gene in 100 Caucasian from a human variation panel and the frequencies estimated by the EM algorithm in STATA 10 (StataCorp, College Station, TX, USA). To test an allele dose effect, the resulting 13 haplotypes (with phase information) were grouped into diplotype 1-4 based on the 1236C4T, 2677G4TA and 3435C4T SNPs in a manner similar to Sissung et al. 36 The 'full wild-type' is thus CGC/CGC (diplotype 1) and the 'full variant type' TTT/TTT (diplotype 3) and the heterotype CGC/TTT (diplotype 2) ( Table 1 ). This approach can possibly reveal effects of interplay between cis variants and are suggested by some to add valuable information that is impossible to achieve by assessing the SNPs separately. [37] [38] [39] Statistical methods Log-transformed clearance was assessed visually to be approximately normal distributed and was used throughout the study. Geometric means are antilog of means of the 
Results
Patients
Total plasma paclitaxel and CrEL concentrations were available from 93 patients. They were recruited from four hospital centers in Denmark: Odense 66 (71%), Herlev 12 (13%), Herning 7 (8%), Vejle 4 (4%) and one in Sweden: Lund 4 (4%). Median age was 60.1 years (range, 32-79.4 years) ( Table 2 ). One additional patient was omitted from analysis because the 18-24 h sample gave consistent results of 3172 ng l -1 (45-fold higher than mean) and a vial mix-up could be excluded. Two patients received bevacizumab from the second cycle (subsequent to the plasma sampling cycle). Three patients used a CYP3A4/5 inhibitor before or during the course wherein PK samples were taken. One patient used ketoconazole, the two others used fluconazole. The individual clearance estimates of unbound paclitaxel for these three patients were 383, 456 and 282 l h -1 , respectively (Figure 1) . No significant correlation between genotypes and BSA, age, bilirubin and performance status was found (data not shown).
Paclitaxel pharmacokinetics
The nonlinear mixed effects model fitted the data well as indicated by goodness-of-fit plots (not shown) and previous data using this model (Table 3) . Overall geometric mean of clearance of unbound paclitaxel was 385 l h -1 (range 176-726 l h -1 ). Typical estimates of compartment volumes and inter compartmental clearances and relative standard errors were similar to those earlier reported 27, 41 (Table 3 ). The model predicts that: an increase in BSA of 0.1 m 2 increases the typical value of clearance by 6.2%, an increase in age of 10 years decrease the typical value of clearance by 6% and the typical value of clearance for patients with WHO/ECOG performance status of 0-1 was 396 l h -1 compared with 304 l h -1 for performance status 2. The average measured CrEL concentration and range were 4.10 vol/vol % (2.63-6.67%), 3.32 vol/vol % (2.25-5.81%) and 2.07 vol/vol % (1.10-3.39%) for the first, second and third sampling, respectively.
Results of genotyping and haplotype inference
Twenty-two SNPs were analyzed in 10 genes. Candidate SNPs were split, a priori, into two groups; one for confirmative type analysis and one for exploratory analysis (Table 4) . Allele frequencies were all similar to frequencies reported in the NCBI SNP database (http://www.ncbi.nlm. nih.gov/sites/entrez?db ¼ snp). The genotype distributions were all in Hardy-Weinberg equilibrium (numbers not shown) except CYP2C8*1B, ABCG2 (c.421C4A) rs2231142 and CYP1B1*3 where the P-values of Pearson's w 2 statistic were 0.03, 0.05 and 0.01, respectively. Inferring haplotypes in ABCB1 resulted in 13 haplotypes (data not shown) with frequencies from 0.5 to 27.4%. Frequencies were comparable with a previous report by Kroetz et al.
35
Genotype vs paclitaxel clearance The confirmative analysis: The CYP2C8*3 genotype was associated with an 11% lower clearance of unbound paclitaxel, which was statistically significant with a P-value of 0.03 (Figure 1) . No significant correlation was found between clearance and ABCB1 C1236T, G2677T/A and C3435T genotypes (Table 4) . Analysis of ABCB1 'haplotypes' performed using the BIMBAM software showed no association with clearance for any single SNP or any two or three SNP combination (data not shown). No significant Impact of CYP2C8*3 on paclitaxel clearance TK Bergmann et al association was found between diplotype group 1-3 and clearance (P-value of 0.12) using linear regression trend-test controlled for BSA, age and performance status (Table 1 ).
Explorative analysis: seven patients with the CYP2C8*4 (c.792C4G) variant had 18% lower mean clearance (geometric) of unbound paclitaxel than wild-type individuals (Table 4) , P-value 0.04. The one individual carrying both the CYP2C8*3 and *4 variant had a clearance of 270 l h -1 . For the intronic SNP in ABCC1 (rs504348) carrying one or two variant alleles were associated with 7% lower clearance of unbound paclitaxel, P-value 0.04. P-values for the exploratory analysis are reported without any correction for multiple testing and should be interpreted accordingly.
Discussion
Our study tests the hypothesis that genetic variants in CYP2C8 and ABCB1 contribute to the observed interindividual variability in paclitaxel clearance. We found evidence supporting a reduced clearance among patients carrying the CYP2C8*3 and possibly also the *4 variant. These results confirm the finding in a pilot study on 33 ovarian cancer patients treated in Sweden. 42 To our knowledge, this is the largest prospective study reporting this association. The results, however, are in somewhat contrast to Henningsson et al. 43 who found no correlation between clearance and CYP2C8*3, CYP2C8*4 and ABCB1 C3435T in 97 patients (male and female) treated with paclitaxel (80-225 mg m -2 ) and Marsh et al. 44 who found no correlation between clearance and CYP2C8*3, CYP2C8*4, ABCB1 C1236T and ABCB1 G2677T in 93 patients with breast cancer treated with 24-h paclitaxel infusion (575-775 mg m -2 ). This discrepancy can be explained by chance or: in case of the study by Henningsson et al., by gender in so far that Joerger et al. 45 showed a 20% higher elimination of paclitaxel in males than in females, and in the case of the study by Marsh et al. 46 by the nonlinear elimination of paclitaxel reported in the studied population. In the pilot study of 33 patients, 42 the rare genotype 2677GA was associated with increased clearance of paclitaxel compared with 2677TT and 2677GG. In this study, five patients carried the 2677A allele but although the patient with the highest clearance among all patients (726 l h -1 ) carried this allele no significant association was found in this study (data not shown). Baker et al. 47 studied docetaxel in 92 patients and found no correlation between docetaxel clearance and ABCB1, ABCC2 and SLCO1B3 variants, but they did report a 64% increase in clearance for the simultaneous presence of CYP3A4*1B and CYP3A5*1A. This finding was not replicated in our study (data not shown).
In the exploratory analysis, a possible association between an intronic SNP in ABCC1 (rs504348) and clearance was found. To our knowledge, this has not been reported in the literature before. However, replication in future studies are warranted before any conclusions can be made regarding this association because the multiple testing makes a spurious finding more likely. The only support in the literature is contradicting evidence supporting a role of ABCC1 in taxane metabolism in vitro 48, 49 and a single report of a possible relationship to a clinical (in vivo) outcome. Wt/*3 CYP2C8*3 genotype Figure 1 Estimates of clearance of unbound paclitaxel as function of CYP2C8*3 genotype for 93 patients with ovarian cancer. The clearance of the three patients concomitantly using a CYP3A4/5 inhibitor are marked with black diamonds (none carried the *3 variant). Means are indicated by the horizontal line. The linear regression analysis of clearance and genotype controlled for BSA, age and performance status showed that patients carrying the CYP2C8*3 variant had a statistically significant lower mean clearance with P-value of 0.03 (uncontrolled P-value 0.04). Wt, wild type. Impact of CYP2C8*3 on paclitaxel clearance
TK Bergmann et al
The geometric mean of paclitaxel clearances across diplotype 1-3 is 399, 381 and 355 l h -1 , which suggest a trend; however, it did not reach the level of statistical significance (P-value 0.12).
Although not the aim of the study, our results support the finding by Joerger et al. 45 that age is negatively correlated and BSA positively correlated to paclitaxel clearance; the 11% decrease in clearance of unbound paclitaxel explained by CYP2C8 variant is comparable in size to the effects of ) and 291 l h -1 (176;468 l h -1 ) for performance status 0-1 and 2 respectively. This effect on clearance of a 'non-fixed' variable provides a competing and dynamic biological explanation for clearance that certainly should be Geometric mean clearance of unbound paclitaxel with 10th and 90th percentiles observed in parentheses. e P-values for the linear regression analysis (trend) of clearance and genotype controlled for body surface area, age and performance status with uncontrolled P-values shown in parentheses. f RS number referring to the SNP database (http://www.ncbi.nlm.nih.gov/sites/entrez?db ¼ snp). g The five patients carrying the A allele were omitted from the analysis.
Impact of CYP2C8*3 on paclitaxel clearance TK Bergmann et al controlled for in the analysis. Omitting patients with performance status 2 from analyses like this might provide a clearer signal, but on the other hand, information regarding an important subgroup would be lost. Although we did observe an association between CYP2C8*3 and clearance of unbound paclitaxel, and causality of the association is scientifically plausible-the magnitude of the effect (that is, approximately 11%) is somewhat disappointing. Even if we assume that the clearance is tightly correlated to the efficacy or toxicity of paclitaxel-genotyping for CYP2C8*3 in clinical practice is not rational at this point in time because the effect is too small. The variability is likely explained by multiple small effect factors both genetic and environmental. It can be speculated that if individualized treatment with paclitaxel is to become a reality in the future and CYP2C8*3 genotyping is to have a role therein, it must be in combination with multiple other factors.
In conclusion, the study provides evidence supporting a contribution from the CYP2C8*3 variant and possibly also the CYP2C8*4 and ABCC1 (rs504348) variants to the variability of paclitaxel clearance. In future studies (of paclitaxel), it might be worthwhile to consider pooling patients with the CYP2C8*3 and *4 variant into one group. Our finding is important in general because it adds to our understanding of inter-individual variability in pharmacokinetics and in particular because it contributes to the growing field of taxane pharmacogenomics.
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